EU UK regulation -- Discussion thread

Status
Not open for further replies.

rolygate

Vaping Master
Supporting Member
ECF Veteran
Verified Member
Sep 24, 2009
8,354
12,402
ECF Towers
@Tom
Just what I've been told, as yet. I've asked for confirmation.

@D103
OK.

We don't know how things will turn out in the UK, it all depends on what the government agency concerned decide to do, and perhaps on what they are told to do. Best case is they walk away, worst case is they ban (licence) ecigs. That will cause a massive change in supply here and put up prices, but in the end it will be business as usual because 'unlicensed medicines' aren't illegal to use or to import, just to sell from a UK base.

As in any commercial operation, businesses will then be competing on who can provide the best prices and service, but from an offshore base.

It would be a lot less painful if the government agency concerned backed out gracefully, but the problem is that such agencies are institutionally incapable of foreseeing the consequences of their actions.
 

Tom09

Super Member
ECF Veteran
Feb 22, 2009
504
125
Germany
As elsewhere posted by Kate:

This is a report from an independent government policy committee.

9 June 2010
OPINION


Consultation on regulation of nicotine containing products

Introduction

1. The Medicines and Healthcare products Regulatory Agency (MHRA), an executive agency of the Department of Health (DH), is consulting on introducing new regulations on nicotine containing products (NCPs) (excluding tobacco). At present any nicotine containing product that claims or implies that it can help with the cessation of smoking is considered a medicinal product by presentation and is regulated by MHRA (“regulation by claims”). These products are widely referred to as Nicotine Replacement Therapy (NRT). However, there are a number of NCPs, such as electronic cigarettes, which do not currently make such claims and hence are not regulated by MHRA.

2. MHRA believes that the regulation of all NCPs will “protect public health from products that have not been assessed for safety, quality and efficacy”. Any requirement for NCPs to be brought within medicine licensing would apply throughout the UK1.

3. The RPC has looked at the quality of evidence and analysis provided in the consultation letter2 and accompanying impact assessment (IA) and, following a meeting with MHRA and DH, would like to make the following comments.


Summary Opinion

4. The RPC is of the opinion that the IA and consultation letter do not provide sufficient evidence to suggest that there is a significant risk to public health from currently unlicensed NCPs which would justify the future regulation of these products. MHRA should have made clearer what evidence is available to suggest there are safety and public health concerns about these products and considered a wider range of policy options before consulting on the introduction of a mandatory licensing requirement for all NCPs. In addition, the data and assumptions used in the IA for estimating the costs and benefits of the new regulations do not appear to be robust.


Detailed Opinion

Policy background and rationale

5. Following a recent review of its current policy on the application of the definition of a medicinal product in the context of nicotine and, after obtaining legal advice, MHRA has concluded that nicotine may potentially fall within medicines legislation because it affects human metabolism. MHRA is therefore proposing to regulate all NCPs (“regulation by function”), which means that all currently unlicensed products containing nicotine (excluding tobacco products) will either need to be removed from the market or licensed by a specific date. However, if MHRA considers changing its practice from regulating “based on claim” to a “regulation by function” principle, then it is not clear from the consultation letter how this will affect tobacco products (e.g. cigarettes), which also contain nicotine and hence will be within scope for these new regulations. MHRA has told the RPC that the tobacco products are excluded from this consultation as they have a separate regulatory regime and have no medicinal function.

6. It is not clear from the consultation letter or IA what specific policy problem MHRA is trying to address through the proposed new regulations. MHRA claims that the licensing of all NCPs is needed “in order to ensure there is no risk to public health from these products” (paragraph 18 of consultation letter). However, the evidence provided in the IA and consultation letter is not sufficient to conclude that there are serious risks to public safety and health to warrant regulatory intervention. In fact, the consultation letter itself acknowledges that the risk to the public health from NCPs is “unknown” (paragraph 17 of the consultation letter). MHRA has informed the RPC that there is potentially a legal obligation to licence these products. However, this issue is not clearly discussed and presented in the IA. The RPC also understands there is some limited evidence of potential harm from testing carried out by the US Food and Drug Administration.

Options

7. The IA considers two options in addition to the “do nothing” option. These two options both propose the regulation of all currently unlicensed NCPs, and the only difference between them is the proposed timeline for implementation of licensing requirements. It appears that Option 1, which provides a much shorter transition period (21 days) than Option 2 (implementation by June 2011), is preferred by MHRA on the grounds of being consistent with their current practice. In addition, the “do nothing” option is not developed because MHRA believes that “it is neither in the public health interest nor commercial interest to leave the current regulation of NCP/NRTs untouched” (paragraph 10 of the IA).

8. Subsequent to this the RPC believes that the range of options considered is too limited and the selection of the preferred option is not based on a robust appraisal of alternative options and their costs and benefits.

Costs and benefits

9. The data and assumptions used in the cost and benefit analysis of the IA do not seem to be robust. In the consultation letter MHRA acknowledges that the number of manufacturers of unlicensed NCPs and the number of products on the UK market are unknown. However, the IA estimates of costs and benefits are based on the assumption that there are 24 manufacturers and 50 products available on the UK market currently. However, the origin of these numbers is not provided and this raises concerns about the subsequent quality of cost estimates. MHRA has told the RPC that these estimates were based on the number of importers contacting the agency about licensing requirements. This needs to be clearly explained and presented in the IA.

10. MHRA estimates that there will be 1,312 additional permanent quitters of tobacco product users as a result of licensing of all NCPs. However, the assumptions and analysis behind this estimate do not appear to be supported by strong evidence. For example, the assumption that the proposed new regulations will bring a further 5% reduction in the number of individuals who permanently quit smoking using licensed NCPs per year is not based on a robust evidence and analysis.

11. Also, it is assumed that 50% of producers of currently unlicensed NCPs will obtain licences. It is not clear on what basis this assumption is made, nor is it clear why the cost of the remaining manufacturers and importers (for not being able to sell their products in the UK market) is not included in the cost estimates.

Impact on competition

12. The IA does not provide an appropriate assessment of the impact of the proposed regulations on competition. For example, the IA claims that all businesses will be equally affected by the regulations, while at the same time it assumes that at least 50% of manufacturers will be required to remove their products from the market as a consequence of the regulations.

13. The regulations are likely to create additional barriers for entry for new producers and importers of NCPs, which is not fully discussed in the IA. According to MHRA the European Commission has said that nicotine could fall within the medicines licensing regime. It is however not clear how consistent the proposed new regulations are with European Internal Market rules and how effectively they would be enforced to achieve their aims in this context.

14. The RPC is pleased to note that MHRA acknowledges the deficiencies in the existing analysis and evidence base, and the way the available evidence is presented in the consultation letter and the IA. The RPC hopes that these shortcomings will be addressed in the next version of the IA.


Michael J S Gibbons OBE
Chair
http://regulatorypolicycommittee.in...ng-Products-final-opinion-for-publication.pdf
 

rolygate

Vaping Master
Supporting Member
ECF Veteran
Verified Member
Sep 24, 2009
8,354
12,402
ECF Towers
Thanks for that, Tom

The RPC is advising that the MHRA's Impact Assessment is faulty. They advise that a new IA is needed.

This probably makes no substantial difference and MHRA will doubtless continue as before. They will author a new IA but ensure that the new version is more acceptable, by carefully adjusting the assessment to show minimal negatives.

They will carefully omit to mention that 99% of the trade will continue from offshore and therefore the entire exercise is completely pointless and will only serve to destroy several businesses, put many people out of work, take a large amount of tax revenue out of the system, and cost other departments of government such as social services and legal services a lot of money.

I especially liked their estimate that 50% of importers would license their products. I'm not sure how 3 or 4 out of 25 equals 50% but then again their maths does work in a different way to the norm. The cost to the country will be measured in millions but I doubt that will figure in the IA anywhere.
 

rolygate

Vaping Master
Supporting Member
ECF Veteran
Verified Member
Sep 24, 2009
8,354
12,402
ECF Towers
On reflection there are several things that can be deduced from reading between the lines of the RPC report.

Firstly, this looks like a CYA job: somebody, somewhere has finally realised that there will be some fallout from this as it's a hot potato on a large scale. That means it's CYA time and those who might catch some blame need to make sure they aren't included when the stuff hits the fan.

The statement that "MHRA's figures do not seem robust" is continually repeated in one form or another, meaning that RPC is saying that the numbers don't add up. This is fairly obvious although the criticism of MHRA's research will probably not stop the process, just ensure that their next documentation is better presented.

In the end RPC do not have the power to stop mistakes at an early stage, just comment on the process, and they are voicing their misgivings - a wise move since if things go pear-shaped they are covered. But MHRA look to be on a railway track and there seems no way to get off now.

On the other hand, this is certainly an extremely positive sign, as the only thing that can possibly stop MHRA's descent into fiasco is pressure from other government agencies - who will bear the brunt of the error, of course. At least, we are now seeing that not everyone in government is blind.


.
 

freakindahouse

Senior Member
ECF Veteran
Mar 17, 2010
211
158
Gloucester
The fundamental problem for the MHRA remains the same for a new IA as it was for the first one, and it's two-fold: firstly, they don't have the first clue about electronic cigarettes, or (frighteningly!) nicotine, as was made abundantly clear at the meeting; secondly, they can carry out impact assessments until they are blue in the face, but unless they are going to force a child to drink eliquid to the point of death or serious harm, they are not going to be able to find any evidence to suggest that electronic cigarettes are dangerous. Such evidence is not available to them (or to the FDA) because such evidence does not exist, despite the fact that ecigs have been in the global marketplace for in excess of 6 years, and are currently regularly used by millions of people around the world.

Good luck, MHRA, if you try to come back with another IA. It cannot be done any better than it was the first time - and we're all aware how shoddy that was! - because it cannot be done in your (paymasters')favour AT ALL!

BTW, I think we may have missed a trick in this thread. That post with the link to another response? From the Royal Pharmaceutical Society? Wow! That is sooooooo embarrassing for the MHRA! I don't know if you guys are aware of it, but there exists a Memorandum of Understanding between the MHRA and the Royal Pharmaceutical Society of Great Britain, which makes for rather interesting reading. Check it out (if you can be bothered!): http://www.rpsgb.org.uk/pdfs/rpsgbmhramou0803.pdf

Now, when we consider that the MHRA has just had its knuckles rapped to the point of disintegration by their own regulators, its more than a little suspicious that the last paragraph of Big Pharma's response to the waste-paper that is MLX364 states:

"Based on the very limited data available concerning the quality, safety and efficacy of unlicensed NCPs on the market, the Society supports policy option 1: 'All NCPs should be classified as medicinal products and all unlicensed NCPs be removed from the market within 21 days'.

We hope these comments are useful.

Thank you for contacting the Society."

(Bear in mind whose products our infinitely superior electronic cigarettes threaten.)

In the aforementioned Memorandum of Understanding, under the heading 'Scope and Purpose', at para 2.2 it says:

"It [this memorandum] outlines the basis of co-operation and collaboration between the two organisations. This includes practical arrangements designed to ensure that the relationship is effective and that together we meet our aims and objectives, particularly when there are overlapping interests and responsibilities." (my emphasis)

Correct me if I'm wrong, but there are some conspiracy theorists out there who might suggest that this borders on being documented evidence of extraordinary competitive corruption. (I'm not one of them, you understand. I merely point out that such may exist! :evil:)

Food for thought, MHRA. You might want to off-load this particular hot potato and walk away with your heads bowed in shame (with your sore knuckles dragging along the ground) while you still can. If an attempt is made to return with a redrafted IA, it can only end in disaster - and public humiliation of the worst kind!

Just my opinion, for what it's worth. :toast:

Cheers - let's all celebrate a great victory for vapers!

Katherine
 

Nick O'Teen

Super Member
ECF Veteran
Mar 28, 2009
510
10
58
Swansea, Wales
www.decadentvapours.com
I can't see how they can possibly shoehorn another IA into the process at this late stage (after they've finished accepting responses.) Given that the inadequate initial consultation with the industry is a key criticism, they won't get away without repeating the whole consultation process as well (if they have the stomach for it,) - it's basically back to square 1 as I see it :)

If they do try to force it through in its current shape, a legal injunction would not be hard to achieve - the RPC's done most of our work for us to discredit the current process, and I'm sure the MHRA's lawyers would advise them of this.

And as Katherine says, they can look for evidence of risk until they're blue in the face - they won't find any, because there isn't any. For all the crazy ways folks find to meet their maker, there's no record of even a hospitalization as a result of ecigs (which can't be said for the licensed NRT products that are packaged with no CHIP-compliant labelling or childproof caps,) let alone a death!

The only positive thing they could say about the MHRA was that at least they accept they've made a complete hash of it :

14. The RPC is pleased to note that MHRA acknowledges the deficiencies in the existing analysis and evidence base, and the way the available evidence is presented in the consultation letter and the IA. The RPC hopes that these shortcomings will be addressed in the next version of the IA.

Yep, back to square 1 I think.
 
Last edited:

rolygate

Vaping Master
Supporting Member
ECF Veteran
Verified Member
Sep 24, 2009
8,354
12,402
ECF Towers
With luck there should be enough legal basis to contest the MHRA process now. In addition to the previously existing issues, the fact that RPC is highly critical (in government terms) of MHRA's evidence base may mean that they must start the process again, or face the possibility of the trade asking the courts to rule against them.

Of course, you only get the justice you can afford. No money = no justice. But with enough grounds to proceed, suppliers might decide to pool their resources and fight. It would certainly be far cheaper than licensing, in any case.

The LACORS affair might lend some weight to this as it shows a willingness by government agencies to act together in an unfair restriction of trade. MHRA admitted working with LACORS on the regulation issue; the subsequent publication of a farago of false information and accusations by LACORS indicates an attempt to mislead the public and create opposition to ecigarettes.

Add to this the manipulation of the market research results by MHRA due to their giving the focus groups false information, and you have a concerted attempt by both agencies to pervert the public perception of ecigarettes and influence the outcome of the consultation process.

Together with the faulty evidence base and the incorrect and incomplete analysis it means that both the basis for licensing and the consultation process are severely flawed. It would appear that to proceed now would be to risk losing at law.

As Jason Cropper pointed out, the current two-tier system for nicotine containing products has worked perfectly well up to now and shows no sign of needing intervention. There are consumer NCP products that show no need for an MA, and there are NRTs that need licensing. The two types coexist perfectly well. Ecigarettes are a consumer product like low-tar cigarettes, coffee, condoms or alcoholic drinks.

Just because caffeine can be supplied as a licensed medicine does not mean that coffee needs an MA. And if a pharmaceutical licensing agency wanted to license coffee, and knew very little about it and compounded that ignorance by doing no research, then conspired with another agency to manipulate the public's opinion of coffee by publishing lies about it and fixing the market research results, and published documents that clearly showed they didn't have a clue what the implications of their actions were likely to be - then it is unlikely they would survive the inevitable legal challenge and succeed in requiring coffee products to have a marketing authorisation.

They would be better off walking away at an early stage and finding something else to occupy their efforts; perhaps condoms should be licensed as they are a consumer harm reduction product, they probably encourage people to have more sex and that can't be a good thing, there is a provable risk of heart failure leading to death. Which is a lot more than can be shown for ecigarettes since as Katherine pointed out, after being used by millions of people globally for many years, nobody has even suggested that an ecigarette could cause someone to catch a cold, never mind anything more serious.

Dr Laugesen stated that, "It is impossible for ecigarettes to cause lung cancer". But it is not impossible for government agencies to believe that ecigarettes are the root of all evil, apparently - especially if they threaten the revenues of pharmaceutical companies.
 
Last edited:

hifistud

Super Member
ECF Veteran
Jul 25, 2009
701
170
68
Sunderland, UK
BTW, I think we may have missed a trick in this thread. That post with the link to another response? From the Royal Pharmaceutical Society? Wow! That is sooooooo embarrassing for the MHRA! I don't know if you guys are aware of it, but there exists a Memorandum of Understanding between the MHRA and the Royal Pharmaceutical Society of Great Britain, which makes for rather interesting reading. Check it out (if you can be bothered!): http://www.rpsgb.org.uk/pdfs/rpsgbmhramou0803.pdf

Now, when we consider that the MHRA has just had its knuckles rapped to the point of disintegration by their own regulators, its more than a little suspicious that the last paragraph of Big Pharma's response to the waste-paper that is MLX364 states:

Big Pharma?? Are you aware of the RPS's membership??

pharmacists is who - not pharmaceutical companies.

Cheers - let's all celebrate a great victory for vapers!

Katherine

A tad premature, methinks.
 

rolygate

Vaping Master
Supporting Member
ECF Veteran
Verified Member
Sep 24, 2009
8,354
12,402
ECF Towers
We now have a very powerful card in our hand: the publication of Dr Eissenberg's research trial final report.

This is the third clinical trial that basically states ecigarettes don't do anything. Specifically, the research again proves that ecigarettes either supply no nicotine at all to the user, or such microscopic amounts that they cannot be construed as being a drug delivery device; and that ecigarettes have no effect on the human body and do not affect the user in any way. There is no metabolic effect.

Since there are now three trials with near-identical results, and all three trials can be shown to be valid for numerous reasons, and there are no trials that show different or opposing results, this creates a simple legal fact: ecigarettes don't work and don't do anything.

This is important because there are three main foundations to the MHRA licensing claim: [1] a risk to public health; [2] 'by description'; [3] 'by function'. A product would need to demonstrate a risk to public health, or be marketed as a treatment, or act as a drug delivery device, in order to show a need for regulation.

[1] It would be impossible to provide any evidence for a risk to public health. There are all sorts of statements that could be used to appeal to Sun readers but courts tend to require a higher level of proof. That is unlikely to be forthcoming.

[2] As 99% of suppliers do not market their products as devices to treat a medical condition, but as alternative consumer products, it would be hard to rule that ecigarettes are some form of medicine. The few rogue traders that do this are outside of the mainstream in the same way that internet marketers promote get-rich-quick schemes.

[3] The final piece in the jigsaw is whether ecigs act as a drug delivery device or not. We now have proof they don't.

It is likely that this would remain the case even if trial results were published that reached a different conclusion, since the three trials that state ecigs do nothing and have no medical effect were clearly independent and in some cases might be said to have been funded and/or run by people who were not at all sympathetic to our interests; and a new trial that had different results, if funded or run by persons seeking a different result, could be claimed to be contaminated, in comparison.

Only fully-independent trials reaching a different conclusion, that could also be seen to be equally clean as regards funding or management, could be seen as equally valid (legally). There are results pending from trials by an ecigarette supplier that may have turn out to have conflicting results, but this trial was funded, managed and run by persons who cannot be described in any way as independent, in contrast to the three previous trials.
 

Vocalek

CASAA Activist
Supporting Member
ECF Veteran
I have a question for MHRA.

In your deliberations, you talked with a number of stakeholders who are not affected at all, one way or another, by your decision. You also talked with other stakeholders whose only interest in the question is financial. How much weight have you given to the concerns of the only set of steakholders whose health and very lives are affected -- the current and potential electronic cigarettes consumers?

Did you find out how well the products worked for them? Did you learn the effect it had on their health?

Anti-tobacco organizations who don't like the fact that the vapor looks like smoking will have their feelings hurt if they don't get their own way. Phillip Morris Limited stands to lose revenue from smokers who switch or have already switched to electronic cigarettes, as do the pharmaceutical companies.

Former smokers who relapse to inhaling smoke because you banned their less harmful alternative stand to lose a lot more than money. Millions more continuiing smokers will be denied access to what has proven to be a most effective and life-changing tool. These folks will pay for your decision with their very lives.

One last questoion: What does the "H" stand for in the acronym for your organization's name? If it truly stands for "Health", let's hope you lived up to the name.
 

rothenbj

Vaping Master
Supporting Member
ECF Veteran
Verified Member
Jul 23, 2009
8,248
7,647
Green Lane, Pa
I have a question for MHRA.

In your deliberations, you talked with a number of stakeholders who are not affected at all, one way or another, by your decision. You also talked with other stakeholders whose only interest in the question is financial. How much weight have you given to the concerns of the only set of steakholders...... .

I can see your as pd as I about this turn of events. I've never seen you make a spelling error (probably missed some, but whatever).

I signed up for the UK vapers forum after reading this. It is depressing and disgusting. We just don't seem to have a chance against people with a lot of power to do as they please. :evil::evil::evil::evil::evil::evil:
 

PlanetScribbles

Ultra Member
ECF Veteran
Verified Member
Aug 3, 2009
1,046
124
Londinium, Brittania
If it does happen, then we should all go out and find our local MJ dealer and start using that instead. If it is illegal to do the wrong thing, and illegal to do the right thing, you may as well do the wrong thing and have fun in the process.
I've had it with the BS that is going down over here. Human rights be damned, we are having them rolled back to the stone age. Ban this, ban that, i'm sick of it.
I've already rolled off a five page essay to the PM telling him how disgraceful it is that disabled people are being persecuted here. Telling a person that they are fit for work when they have a terminal illness ffs!
I guess i'll be firing up MS Word again on this issue. Bombard the .......s with snail mails.
 
Status
Not open for further replies.

Users who are viewing this thread